MedTrace Logo

ARTEMIS DIANE T790M (An Amino Acid Substitution at Position 790 in EGFR, From a Threonine (T) to a Methionine (M)) Mutation at Hospital Laboratories in Comparison With Central Laboratory

NCT02991274 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 897

Last updated 2019-06-12

No results posted yet for this study

Summary

The study primary objective is to assess the concordance of T790M resistance mutation testing from hospital-based laboratories with T790M resistance mutation testing from a central laboratory.

Conditions

  • Locally Advanced or Metastatic EGFR(+) NSCLC Patients

Interventions

PROCEDURE

genomic testing of T790M mutation

patients will need to have genomic testing of T790M mutation at hospital laboratories and in central laboratory.

Sponsors & Collaborators

Principal Investigators

  • Caicun Zhou · Shanghai Pulmonary Hospital, Shanghai, China

  • Jie He · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

  • Jie Wang · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-16
Primary Completion
2018-06-29
Completion
2018-06-29

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02991274 on ClinicalTrials.gov